FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

Disease Sites:

Miscellaneous

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Enfotumab Vedotin-EV, LOXO-435, Pembrolizumab

Principal Investigator(s):

Tan, Alan

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

12-23-2025

Trial Type:

Treatment

Protocol ID:

VICCURO24518

National Clinical Trial ID:

NCT05614739

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

ALL

Accepts Healthy Volunteers?:

false

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Eligibility